Division of Hematology and Oncology, Department of Medicine, UMass Memorial Health Care
Health Services Administration | Hematology | Hemic and Lymphatic Diseases | Infectious Disease | Neoplasms | Oncology | Virus Diseases
The outbreak of the coronavirus disease 2019 (COVID‐19) has posed an unprecedented challenge to the health care communities across the globe. As of June 17th, 2020, a total of 8,339,829 confirmed COVID-19 cases with 448,420 deaths have been reported . Different parts of the world are seeing different levels of COVID-19 activity with regards to the infection rate, susceptible population, and mortality rate. The COVID-19 pandemic is a rapidly evolving emergency and is a subject of regular debate and advanced research. Patients with hematological disorders and solid malignancies have special needs and oncologists are facing a compound challenge.
COVID-19, Cancer, Hematology, Pandemic
Rights and Permissions
This is an Accepted Manuscript of an article published in Expert Review of Hematology, posted after 12-month embargo as allowed by the publisher's author self-archiving policy at https://authorservices.taylorandfrancis.com/sharing-your-work/#.
DOI of Published Version
Sahu KK, Cerny J. Managing patients with hematological malignancies during COVID-19 pandemic. Expert Rev Hematol. 2020 Jun 25. doi: 10.1080/17474086.2020.1787147. Epub ahead of print. PMID: 32580592. Link to article on publisher's site
Expert review of hematology
Sahu KK, Cerny J. (2020). Managing patients with hematological malignancies during COVID-19 pandemic. COVID-19 Publications by UMass Chan Authors. https://doi.org/10.1080/17474086.2020.1787147. Retrieved from https://escholarship.umassmed.edu/covid19/62